Journal of Nanomaterials

Journal of Nanomaterials / 2017 / Article

Research Article | Open Access

Volume 2017 |Article ID 2898342 | 10 pages | https://doi.org/10.1155/2017/2898342

Preparation and Characterisation of Nobiletin-Loaded Nanostructured Lipid Carriers

Academic Editor: Bo Tan
Received24 Feb 2017
Revised06 Jul 2017
Accepted19 Jul 2017
Published17 Aug 2017

Abstract

The objective of this manuscript was to investigate and optimise the potential of nanostructured lipid carriers (NLCs) as a carrier system for nobiletin (NOB), which was prepared by high-pressure homogenisation method. Additionally, this study was focused on the application of NOB-loaded NLC (NOB-NLC) in functional food. Response surface method with a three-level Box–Behnken design was validated through analysis of variance, and the robustness of the design was confirmed through the correspondence between the values measured in the experiments and the predicted ones. Properties of the prepared NOB-NLC, such as -average, polydispersity, entrapment efficiency, zeta potential, morphology, and crystallinity, were investigated. NOB-NLC exhibited a spherical shape with a diameter of 112.27 ± 5.33 nm, zeta potential of −35.1 ± 2.94 mV, a polydispersity index of 0.251 ± 0.058, and an EE of 81.06%±6.02%. Results from X-ray diffraction and differential scanning calorimetry of NOB-NLC reviewed that the NOB crystal might be converted to an amorphous state. Fourier transform infrared spectroscopic analysis demonstrated that chemical interaction was absent between the compound and lipid mixture in NOB-NLC.

1. Introduction

Nobiletin (5,6,7,8,3′,4′-hexametoxyflavone, NOB) is a citrus polymethoxylated flavone that possesses an extensive range of health benefits among others, including antioxidant activity, glucose regulation, and fat metabolism [1]. It was previously reported that nobiletin could inhibit tumor angiogenesis by regulating Src, FAK, and STAT3 signalling through PXN in ER+ breast cancer cells [2] and also showed its ameliorative effects toward ischemia–reperfusion injury by suppressing the function of Kupffer cells after liver transplantation in rats [3]. Furthermore, nobiletin has been found to have positive effects of nobiletin on propofol-mediated anti-inflammatory as well as having neuroprotective effect [4]. It may represent beneficial drug candidates for the treatment and prevention of Alzheimer’s and Parkinson’s disease because of its naturally occurring phytochemicals [5]. Similar to other flavonoids, NOB exists widely in nature and is found mainly in various citrus peels. Therefore, a citrus processing waste can be potentially converted into a valuable functional ingredient. However, NOB exhibits poor water solubility because all hydroxyl groups in the structure are methoxylated, leading to low oral bioavailability, thus limiting the practical uses of NOB [6].

Delivery systems using lipid-based bioactive components as promising carriers are getting increasing attention nowadays because of their potential to increase solubility and improve bioavailability of water-insoluble and/or lipophilic bioactive components [7]. NLCs are second-generation lipid nanoparticles distinguished from SLN as described by Müller et al. [8, 9]. NLCs possess the advantages related to SLNs, such as feasibility for encapsulation of hydrophobic and hydrophilic compounds and the capability to impart controlled and sustained release characteristics over free-state compound. Furthermore, NLCs have the ability to protect compounds from chemical, physical, oxidative, or light degradation; are of extremely low toxicity; and are also of low cost [10, 11]. NLCs are derived from oil–water emulsions and SLNs by preparing a liquid lipid through a matrix of a solid lipid. Compared with SLNs, this matrix has a less-ordered crystalline nanostructure that imparts higher loading capacity for the compound, overcomes the drawback of the compound expulsion from the lipid core, and now is popularly studied and used in pharmaceutical, cosmetic, and food products [12, 13]. In spite of this, there has been no report about the application of NLC on delivery of NOB. Quite a few examinations have been undertaken to improve the healthful potential of NOB for oral administration by choosing appropriate delivery system, including chitosan-based microemulsions loaded with NOB for intravenous injection [14], self-nanoemulsifying delivery systems [15], NOB-loaded chitosan nanoparticles [16], self-assembling NOB proliposomes [17], and NOB-loaded solid lipid nanoparticles (SLNs) [18]. According to recent researches, nanoemulsion-filled hydrogel could achieve the sustained release and absorption of nobiletin and prevent its precipitation in the gastrointestinal tract [19]. Taken together, these previous findings provided the foundation and evidence for further research on NOB-loaded NLC.

The objectives of this research were as follows: firstly, to study the suitability and the effectiveness of NLCs as a new type carrier system to encapsulate NOB and, secondly, to investigate the characteristics of the prepared NLC. To perform and optimise the formulations, a Box–Behnken design (BBD) of three factors and three levels was used, and high-pressure homogenisation technology was chosen by considering industrial needs [12, 20]. Furthermore, the following characteristics of NLC system were fully examined: particle size, polydispersity index (PDI), zeta potential, entrapment efficiency (EE), morphology and crystallinity through dynamic light scattering (DLS), high-performance liquid chromatography method (HPLC), transition electron microscopy (TEM), differential scanning calorimetry (DSC), Fourier transform infrared (FT-IR), and X-ray diffraction (XRD).

2. Materials and Methods

2.1. Materials

NOB was acquired from Lisi Bio-Tech Inc. (Xi’an, China). Labrafac lipophile WL 1349 and Geleol mono- and biglycerides NF were obtained from Gattefosse (Saint-Priest Cedex, France). Lecithin (containing 90% soybean phosphatidylcholine) was obtained from Shanghai Taiwei Pharmaceutical Co. Ltd. (Shanghai, China). Poloxamer 188 (Pluronic F68®) was a generous gift from BASF (Ludwigshafen, Germany). Methanol and acetonitrile provided by Sigma Co. (St. Louis, MO, USA) were of HPLC grade. Ultrapure water was prepared through a Direct-Q™ instrument (Millipore, Molsheim, France).

2.2. Preparation of NOB-NLC

NOB-NLC was prepared through melt-emulsification technique and high-pressure homogenisation [21]. Briefly, 3 mL ethanol was added as cosolvent to the lipid phase, which was evenly composed of NOB, solid lipid, liquid lipid, and lecithin. A total of 100 mL each of aqueous phase, including surfactant, and lipid phase was heated to 75 ± 3°C in a water bath. Subsequently, the lipid matrix was injected into the aqueous matrix, and the mixture phase was stirred at 500 rpm for 10 min and then mixed by a Lab high-shear homogeniser SRH-S300 (Siehe Industry, Shanghai, China) at 10000 rpm for 2 min at the same temperature. Afterwards, the coarse emulsion was homogenised using a nanohomogeniser machine AH100D (ATS Engineering Inc., Vancouver, Canada) under 800 bar for 10 cycles. Finally, the resulting nanoemulsion was allowed to cool down to room temperature to form NOB-NLC.

2.3. Box–Behnken Design for Optimisation of NOB-NLC

A response surface method (RSM) based on BBD was employed, and a 17-run design with three factors and three levels, which included 12 factorial points and 5 axial points, was carried out in the present work [22]. Meanwhile, Design Expert® 8.0.5 software (Stat-Ease Inc., Minneapolis, USA) was applied to determine the response patterns and then to establish models, which are shown below:

As shown in (1), the measured responses () were mean particle size () and EE (). The three independent variables selected were emulsifier-to-lipid ratio (), lecithin-to-Poloxamer 188 ratio (), and liquid lipid-to-solid lipid ratio () [23]. For each factor, high, medium, and low levels were represented by codes 1, 0, and −1, respectively (Table 1). is the intercept; , , and are the linear coefficients; , , and are the interaction coefficients; and , , and are the quadratic coefficients.


Variables

Independent variables Levels
Low
(−1)
Medium
(0)
High
(+1)

: emulsifier-to-lipid ratio11.752.5
: lecithin-to-Poloxamer 188 ratio0.51.252
: liquid lipid-to-solid liquid ratio0.3311.67

Dependent variables Constraints

: mean particle size (nm) Minimum
: encapsulation efficiency (%) Maximum

2.4. -Average, PDI, and Zeta Potential Characterisation

-average, PDI, and zeta potential of NOB-NLC were analysed through DLS using a Zeta Analyser ZEN-3600 (Malvern Instruments, Worcester, UK). Sample measurements were taken in triplicate at 25°C with a fixed scattering angle of 173°. The collected data were then analysed through the manufacturer-supplied software from Malvern Instruments [24].

2.5. Entrapment Efficiency and High-Performance Liquid Chromatography Measurement

The EE of NOB-NLC was determined by measuring free NOB in the aqueous phase, which was separated using ultrafiltration centrifugation [21, 25]. A total of 500 μL NOB-NLC was added to the upper chamber of Centrifugal Filter Unit 100 kDa (Millipore Co., Boston, USA) and then centrifuged at 3000 rpm for 20 min at 4°C through UniCen MR (Herolab, Germany) [26]. The filtrate was dissolved in methanol and analysed through HPLC using Dionex UltiMate 3000 (Sunnyvale, USA) with C18 column. Chromatographic analysis was performed at 30°C and 333 nm using ultrapure water and acetonitrile (55 : 45 v/v) as the mobile phase, with injection volume of 20 μL and a flow rate of 1.0 mL/min. Acetonitrile and ultrapure water were previously eluted through a 0.22 μm membrane filter. The EE was calculated through the following equation [27]:where is the mass of initial NOB used for the assay and is the mass of free NOB in the aqueous phase.

2.6. Transition Electron Microscopy Analysis

The morphological characteristics of NOB-NLC were observed using TEM JEM-2100 (JEOL Ltd., Tokyo, Japan) at 200 kV. The samples were dropped onto Formvar/Carbon 230 Mesh copper grids (Zhongjingkeyi Technology Co. Ltd., Beijing, China), air-dried at room temperature of about 25 ± 3°C for 24 h, and negatively stained with phosphotungstic acid (1% w/v) for approximately 20 min before observation [26].

2.7. Differential Scanning Calorimetry Measurement

The thermograms of freeze-dried NOB-NLC, blank NLC, and NOB were analysed using DSC Q20 (TA Instruments, New Castle, USA). 3 mg of the samples was placed into standard aluminum pans, and the temperature was then increased from 25°C to 240°C at a heating or cooling scanning rate of 10°C min−1. During thermal scans, dry nitrogen was used as effluent gas and an empty pan as a reference for the analysis [25, 26, 28].

2.8. Fourier Transform Infrared Spectroscopy

The FT-IR spectrum of freeze-dried NOB-NLC, blank NLC, and NOB was examined using FT-IR spectrometer Nicolet 6700 (Madison, USA). The samples were scanned over a wavenumber [29], ranging from 550 cm−1 to 4000 cm−1.

2.9. X-Ray Diffraction Measurements

X-ray diffractometer X’Pert3Power (PANalytical B.V., Almelo, The Netherlands) was chosen to collect and compare the XRD intensity data of lyophilised NOB-NLC, lyophilised blank NLC, and NOB. XRD analysis was performed under CuKα radiation (λ = 1.54056 Å, voltage 40 kV, and current 40 mA) across the diffraction angle range of 0° ≤ 2θ ≤ 90° (step size: 0.013°; scan step time: 8.67 s) [30].

2.10. Data Analysis

All of the experiments were run in triplicate, and results were presented as mean ± SD. Design Expert 8.0.5 software was employed for design and analysis of the data for RSM. Differences were regarded as significant when value < 0.05.

3. Results and Discussion

3.1. Formulation Optimisation of NOB-NLC

Based on the BBD design, 17 different formulations were carried out to determine the most critical independent variables, and the responses are summarised in Table 2. The final parameters that most intensely affected the properties of NOB-NLC were identified to be emulsifier-to-lipid ratio (), lecithin-to-Poloxamer 188 ratio (), and liquid lipid-to-solid lipid ratio (). The polynomial equations were statistically validated through analysis of variance, and a summary of the results of regression analysis of responses is demonstrated in Table 3. The 3D graphs of the response surface plotted to represent the effects of the independent factors on measured responses of mean particle size and EE are shown in Figures 1 and 2.


Formulations Independent variablesDependent variables
Observed valuePredicted value

(1)1.000.501.00157.2671.42
(2)2.500.501.00172.7283.38
(3)1.002.001.00174.9287.24
(4)2.502.001.00121.3868.17
(5)1.001.250.33172.3481.30
(6)2.501.250.33177.9675.77
(7)1.001.251.67149.6559.94
(8)2.501.251.67105.9558.36
(9)1.750.500.33190.0882.62
(10)1.752.000.33175.6783.38
(11)1.750.501.67145.1763.69
(12)1.752.001.67125.8963.54
(13)1.751.251.00102.0683.67
(14)1.751.251.00102.0683.67
(15)1.751.251.00102.0683.67
(16)1.751.251.00102.0683.67
(17)1.751.251.00102.0683.67

= emulsifier-to-lipid ratio, = lecithin-to-Poloxamer 188 ratio, = liquid lipid-to-solid liquid ratio, = mean particle size (nm), and = encapsulation efficiency (%).

Source
Sum of squaresMean square-value valueSum of squaresMean square-value value

Model17876.211986.2512.791557.29173.0310.65
724.99724.994.6725.2825.281.56
567.05567.053.650.180.180.011
4483.494483.4928.86751.17751.1746.24
1190.351190.357.66240.72240.7214.82
607.99607.993.913.903.900.24
5.935.930.0380.210.210.013
2304.092304.0914.83117.79117.797.25
4077.024077.0226.252.862.860.18
2850.962850.9618.35382.74382.7423.56
Residual1087.31155.33113.7116.24
Lack of fit839.49279.834.520.089762.0620.691.60
Cor total247.8361.9651.6512.91
Pure error18963.531671.0
0.94270.9320
CV%8.9%5.28
Adeq Precision9.2089.341

().
3.1.1. Effect on Mean Particle Size

The mean particle size () varied from 95.7 nm (Formulation (13)) to 186.325 nm (Formulation (2)), whereas the average was 139.96 nm as shown in Table 2. The effect of independent variables on mean particle size has been presented through the quadratic equation as follows:

Equation (3) revealed negative effects on the variables , , and on , as indicated by the negative value before the variable in the quadratic equation. Higher emulsifier-to-lipid ratio may promote formation of smaller particles and provide higher stabilisation of nanosystem because of the reduction in interfacial tension between the lipid matrix and the hydrophilic phase [31]. The results showed that as liquid lipid-to-solid lipid ratio increased, particle size decreased from 175.39 nm (Formulation (6)) to 96.93 nm (Formulation (8)), which can be attributed to the increased amount of solid lipids that tend to facilitate the aggregation of particles.

The 3D surface plots for the effect of interaction between , , and on particle size are shown in Figures 1(a)1(c). As shown in Table 3, all independent factors have significant effect on the mean particle size of NOB-NLC (), particularly the liquid lipid-to-solid lipid ratio ( and ). Furthermore, the interaction term of emulsifier-to-lipid ratio and lecithin-to-Poloxamer 188 ratio surfactant () is also significant (), which is consistent with the analysis 3D plot of response surface (Figure 1(a)). In addition, the correlation coefficient () was 0.9427, indicating that merely 5.73% of total variables could not be illustrated by the model. The coefficient of variation was at 8.9%, and the low value suggested that the observed values were consistent with the predicted ones. The signal-to-noise ratio of the model was evaluated by “Adeq Precision” [32], with the value of 9.208 (>4), which indicated the sufficiency of model with mean particle size [33].

3.1.2. Effect on Entrapment Efficiency

In the case of EE, the value ranged from 59.35% (Formulation (8)) to 88.72% (Formulation (17)) with the selected levels of variables, whereas the average was found to be 76.30%. The following quadratic equation showed the effect of various independent factors on EE:

The positive effect of variables , , and on EE could be seen in (4) as the positive value before these variables, as shown in the quadratic equation. Higher emulsifier-to-lipid ratio could induce an increase in EE; the reason might be the availability of adequate emulsifier, which made the compound stay within the lipid particles and/or on the surface of the particles. Therefore, the liquid lipid-to-solid lipid ratio directly affects EE, which can be ascribed to the availability of higher amount of liquid lipid for compound entrapment. This can also be caused by the amphipathy of lecithin. Moreover, the interaction terms and exhibited a negative effect on particle size, whereas revealed positive effects on EE of NOB-NLC [34].

The 3D response surface graphs, which depict the interaction effects of , , and on EE, are presented in Figures 2(a)2(c). The model value less than 0.05 and the -value of 10.65 indicated the significance of the model for EE. Additionally, values of linear coefficient of , interaction term coefficient of , and quadratic term coefficients of and were all above 0.05, implying that they were significant on EE of NOB-NLC. Coefficient of correlation ( = 0.932) and the coefficient of variation were at a low value (5.28%), which suggested a good relevance between predicted and experimental values. The model could be employed to navigate the design space demonstrating that the value of “Adeq Precision” is 9.341 [33].

3.2. Optimisation and Validation

The optimisation of NOB-NLC preparation was chosen based on the prerequisite of fulfilling the minimum mean particle size and maximising the value of EE by applying the optimum formulation point of numerical method generated by Design Expert software. The optimised composition was selected as the emulsifier-to-lipid ratio of 1.76, lecithin-to-Poloxamer 188 ratio of 1.35, and liquid lipid-to-solid lipid ratio of 0.95, which were suggested to attain the prerequisites of the optimised NOB-NLC formulation.

These observed responses of mean particle size (112.27 ± 5.33 nm) and EE (81.06 ± 6.02%), presented by the optimised NOB-NLC formulation, and the predicted value of mean particle size (103.18 nm) and EE (84.28%), generated by the Design Expert software, were found to be in good agreement. This finding demonstrates that the optimised formulation was reliable in predicting the response of the NOB-NLC system.

3.3. Surface Characterisation

The optimised NOB-NLC was homogeneous and slightly bluish, as shown in Figure 3(a). The particles exhibited a size of 112.27 ± 5.33 nm, with a PDI of 0.251 ± 0.058, an EE of 81.06 ± 6.02%, and zeta potential of −35.1 ± 2.94 mV. Studies of receiver biases suggest that the open endothelial gaps were in a range from 100 nm to 1000 nm [35], and particles of small size could trigger a long blood circulation as a free compound. The nanoparticles with a size of 100–300 nm have been found suitable to distribute in a tumor and easily transport through blood brain barriers [36]. PDI values below 0.3 indicated a narrow size distribution, excellent dispersity, and high homogeneity of nanoparticles [37]. The zeta potential played an important role in evaluating the stability of a nanoparticle system; high zeta potential can prevent particles from aggregating through electric repulsion. Currently, if the zeta potential is below −30 mV or above +30 mV, the systems will be considered stable. Furthermore, the powerful statistical obstruction and beneficial static repulsion will contribute to additional stability [38, 39].

TEM images of NOB-NLC (Figure 3(b)) revealed that the optimised nanoparticles were well-identified as spherical, uniform, and nonadherent and were approximately 120 nm in diameter with a dense core (Figure 3(c)), which is accordant with the data estimated through DLS method [40]. Moreover, the particle size measured through DLS, called hydrodynamic size, was found to be larger than that of the TEM results, called actual size. These differences are hypothesised to be attributed to different size measurement methods, as the solvent layer attached to the particle is measured in DLS [36]. Different morphologies have been reported in much of the research in NLC; nevertheless, spherical morphology that has been discovered holds a greater proportion [12]. Previous study indicated that the differences of compositions of lipid and surfactants or photographic equipment employed may result in the distinction in morphology of NLC [41].

3.4. Solid-State Characterisation of NOB-NLC Systems: DSC Data

Figure 6 shows the modulated DSC scans of the freeze-dried NOB-NLC, blank NLC, and NOB. A sharp endothermic peak was observed in the crystalline NOB at 137.03°C, which was in concert with its melting point (Figure 4(c)). The melting of blank NLC peaked at 48.73°C with a small shape (Figure 4(a)), and a lower melting peak of NOB-NLC appeared at 50.58°C in the thermogram (Figure 4(b)). In the NOB-NLC formulations, the NOB melting could not be detected, which could be attributed to the existence of NOB in the amorphous state or in a molecularly dispersed state within the lipid matrix. Even if a small fraction of NOB is present in NOB-NLC as undissolved material in the crystalline state, the relatively low compound loading of NOB in NOB-NLC would render NOB-NLC improbable to detect the melting event of any such fraction using a DSC-based technique [42]. This phenomenon can also be ascribed to the interference of NOB and the surfactants in NOB-NLC crystallisation [43]. Furthermore, according to Gibbs–Thomson equation, particle size also has a conspicuous effect on the melting endotherm of lipid particles in nanoscale range [44]. Different lipid nanoparticles melted at different temperatures and led to peak broadening and a change in melting transition to lower temperature on the basis of this equation, as was different from that of mass lipid [36].

3.5. Solid-State Characterisation of NOB-NLC Systems: FT-IR Data

The overlay spectra of freeze-dried NOB-NLC, blank NLC, and NOB are shown in Figure 6. The IR spectrum of NOB (Figure 6(c)) revealed the characteristic absorption bands at 1643.54 (-C=O, aromatic ketone), 1587.13 (C-C, aromatic ring), 1013.89 (C-O stretch), and 2944.77 cm−1 (C-H stretch). In NOB-NLC, these peaks appeared at 1644.02 (-C=O, aromatic ketone), 1586.16 (C-C, aromatic ring), 1014.86 (C-O stretch), and 2952.48 cm−1 (C-H stretch) (Figure 5(c)). This confirmed the presence of NOB in NOB-NLC, indicating that no chemical interaction between the compound and lipid excipients took place. The IR spectra of blank NLC (Figure 5(a)) and NOB-NLC (Figure 5(b)) were clearly suggestive of the presence of another crystalline form in NOB-NLC, which was further confirmed using DSC. The slight shift and decrease of absorption bands of NOB in NOB-NLC can be ascribed to a transformation in molecular environment and intermolecular interactions accompanied by dispersed compound molecule in lipid matrix [36].

3.6. Solid-State Characterisation of NOB-NLC Systems: XRD Data

XRD experiments were performed to investigate the changes of the microstructure in the lipid crystallisation process (Figure 6). The XRD spectra of NOB in Figure 6(c) showed distinct and intense peaks at 2θ scale, indicating the high crystalline structure of NOB (i.e., three sharp peaks at 2θ = 7.68°, 11.47°, and 11.86°; five medium-intensity peaks at 2θ = 8.99°, 10.19°, 12.46°, 15.28°, and 18.84°; and several low-intensity peaks at 2θ = 5.97°, 9.64°, and 13.42°). Characteristic peaks of NOB were absent from the XRD pattern of NOB-NLC (Figure 6(b)), indicating that the NOB molecule lost its crystalline nature and formed an amorphous complex with the NLC matrix. This discovery corresponds to the result from the DSC analysis, providing evidence of the phase transition of NOB from crystalline to amorphous during processing [45].

4. Conclusion

NOB-loaded NLCs were successfully developed through a high-pressure homogenisation technique and optimised by seventeen-run, three-factor, three-level BBD. The lecithin-to-Poloxamer 188 ratio and the liquid lipid-to-solid lipid ratio were crucial determinants for NOB-NLC production as these factors influenced the physical properties of NOB-NLC. The optimised NOB-NLC manifested a size of 112.27 ± 5.33 nm with a polydispersity of 0.251 ± 0.058, an EE of 81.06 ± 6.02%, and zeta potential of −35.1 ± 2.94 mV. Particle size and TEM study confirmed nanosized discrete spherical globules with a smooth surface area. DSC and XRD confirmed the transformation of the crystalline nature of NOB into an amorphous nature, which played an important role in the enhancement of absorption rate, followed by NOB bioavailability. FT-IR analysis confirmed the efficient entrapment of NOB in NOB-NLCs. Thus, this present research demonstrated that the optimised formulation has potential in delivering NOB and other lipophilic compounds. Future research should focus on the appraisal of the practical potential of the optimum formulation in food-relevant models and actual food systems during production and storage.

Conflicts of Interest

The authors declare that they have no conflicts of interest.

Acknowledgments

This research is funded by Chongqing Research Program of Basic Research and Frontier Technology (no. cstc2016jcyjA0552), Special Fund for Agro-Scientific Research in the Public Interest (201303076-07), and Chinese National Natural Science Foundation (31601396).

References

  1. S. Li, H. Wang, L. Guo, H. Zhao, and C.-T. Ho, “Chemistry and bioactivity of nobiletin and its metabolites,” Journal of Functional Foods, vol. 6, no. 1, pp. 2–10, 2014. View at: Publisher Site | Google Scholar
  2. N. Sp, D. Kang, Y. Joung et al., “Nobiletin inhibits angiogenesis by regulating Src/FAK/STAT3-mediated signaling through PXN in ER+ breast cancer cells,” International Journal of Molecular Sciences, vol. 18, no. 5, p. 935, 2017. View at: Publisher Site | Google Scholar
  3. Y. Wu, W. Zhang, M. Li, D. Cao, X. Yang, and J. Gong, “Nobiletin ameliorates ischemia-reperfusion injury by suppressing the function of Kupffer cells after liver transplantation in rats,” Biomedicine Pharmacotherapy, vol. 89, pp. 732–741, 2017. View at: Publisher Site | Google Scholar
  4. Y. Zheng, J. Bu, L. Yu, J. Chen, and H. Liu, “Nobiletin improves propofol-induced neuroprotection via regulating Akt/mTOR and TLR 4/NF-κB signaling in ischemic brain injury in rats,” Biomedicine Pharmacotherapy, vol. 91, pp. 494–503, 2017. View at: Publisher Site | Google Scholar
  5. N. Braidy, S. Behzad, S. Habtemariam et al., “Neuroprotective effects of citrus fruit-derived flavonoids, nobiletin and tangeretin in alzheimer's and parkinson's disease,” CNS and Neurological Disorders Drug Targets, 2017. View at: Google Scholar
  6. S. Onoue, A. Uchida, H. Takahashi et al., “Development of high-energy amorphous solid dispersion of nanosized nobiletin, a citrus polymethoxylated flavone, with improved oral bioavailability,” Journal of Pharmaceutical Sciences, vol. 100, no. 9, pp. 3793–3801, 2011. View at: Publisher Site | Google Scholar
  7. C. M. O'Driscoll and B. T. Griffin, “Biopharmaceutical challenges associated with drugs with low aqueous solubility—The potential impact of lipid-based formulations,” Advanced Drug Delivery Reviews, vol. 60, no. 6, pp. 617–624, 2008. View at: Publisher Site | Google Scholar
  8. R. H. Müller, M. Radtke, and S. A. Wissing, “Solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) in cosmetic and dermatological preparations,” Advanced Drug Delivery Reviews, no. 54, pp. 131–155, 2002. View at: Google Scholar
  9. R. H. Müller, M. Radtke, and S. A. Wissing, “Nanostructured lipid matrices for improved microencapsulation of drugs,” International Journal of Pharmaceutics, vol. 242, no. 1-2, pp. 121–128, 2002. View at: Publisher Site | Google Scholar
  10. M. D. Joshi and R. H. Müller, “Lipid nanoparticles for parenteral delivery of actives,” European Journal of Pharmaceutics and Biopharmaceutics, vol. 71, no. 2, pp. 161–172, 2009. View at: Publisher Site | Google Scholar
  11. R. H. Müller, R. D. Petersen, A. Hommoss, and J. Pardeike, “Nanostructured lipid carriers (NLC) in cosmetic dermal products,” Advanced Drug Delivery Reviews, vol. 59, no. 6, pp. 522–530, 2007. View at: Publisher Site | Google Scholar
  12. C. L. Fang, S. A. Al-Suwayeh, and J. Y. Fang, “Nanostructured lipid carriers (NLCs) for drug delivery and targeting,” Recent Patents on Nanotechnology, vol. 7, no. 1, pp. 41–55, 2013. View at: Publisher Site | Google Scholar
  13. F. Tamjidi, M. Shahedi, J. Varshosaz, and A. Nasirpour, “Nanostructured lipid carriers (NLC): a potential delivery system for bioactive food molecules,” Innovative Food Science and Emerging Technologies, vol. 19, pp. 29–43, 2013. View at: Publisher Site | Google Scholar
  14. J. Yao, J. P. Zhou, Q. N. Ping, Y. Lu, and L. Chen, “Distribution of nobiletin chitosan-based microemulsions in brain following i.v. injection in mice,” International Journal of Pharmaceutics, vol. 352, no. 1-2, pp. 256–262, 2008. View at: Publisher Site | Google Scholar
  15. H. Chen, Y. An, X. Yan, D. J. McClements, B. Li, and Y. Li, “Designing self-nanoemulsifying delivery systems to enhance bioaccessibility of hydrophobic bioactives (nobiletin): influence ofhydroxypropyl methylcellulose and thermal processing,” Food Hydrocolloids, vol. 51, pp. 395–404, 2015. View at: Publisher Site | Google Scholar
  16. A. G. Luque-Alcaraz, J. Lizardi, F. M. Goycoolea et al., “Characterization and antiproliferative activity of nobiletin-loaded chitosan nanoparticles,” Journal of Nanomaterials, vol. 2012, Article ID 265161, 7 pages, 2012. View at: Publisher Site | Google Scholar
  17. W. Lin, J. Yao, and J. Zhou, “Preparation of self-assemble nobiletin proliposomes and its pharmacokinetics in rats,” Acta Pharmaceutica Sinica, vol. 44, no. 02, pp. 192–196, 2009. View at: Google Scholar
  18. X. F. Zhang, C. F. Xing, and Q. T. Guo, “Preparation of nobiletin solid lipid nanoparticles,” Chinese Traditional Patent Medicine, vol. 36, no. 09, pp. 1857–1862, 2014. View at: Google Scholar
  19. L. Lei, Y. Zhang, L. He, S. Wu, B. Li, and Y. Li, “Fabrication of nanoemulsion-filled alginate hydrogel to control the digestion behavior of hydrophobic nobiletin,” LWT—Food Science and Technology, vol. 82, pp. 260–267, 2017. View at: Publisher Site | Google Scholar
  20. G. Calixto, J. Bernegossi, B. Fonseca-Santos, and M. Chorilli, “Nanotechnology-based drug delivery systems for treatment of oral cancer: a review,” International Journal of Nanomedicine, vol. 9, no. 1, pp. 3719–3735, 2014. View at: Publisher Site | Google Scholar
  21. M. Li, Y. Zheng, F.-Y. Shan, J. Zhou, T. Gong, and Z.-R. Zhang, “Development of ionic-complex-based nanostructured lipid carriers to improve the pharmacokinetic profiles of breviscapine,” Acta Pharmacologica Sinica, vol. 34, no. 8, pp. 1108–1115, 2013. View at: Publisher Site | Google Scholar
  22. M. Kamran, A. Ahad, M. Aqil, S. S. Imam, Y. Sultana, and A. Ali, “Design, formulation and optimization of novel soft nano-carriers for transdermal olmesartan medoxomil delivery: in vitro characterization and in vivo pharmacokinetic assessment,” International Journal of Pharmaceutics, vol. 505, no. 1-2, pp. 147–158, 2016. View at: Publisher Site | Google Scholar
  23. C. L. Ngan, M. Basri, F. F. Lye et al., “Comparison of Box-Behnken and central composite designs in optimization of fullerene loaded palm-based nano-emulsions for cosmeceutical application,” Industrial Crops and Products, vol. 59, pp. 309–317, 2014. View at: Publisher Site | Google Scholar
  24. M. Shangguan, Y. Lu, J. Qi et al., “Binary lipids-based nanostructured lipid carriers for improved oral bioavailability of silymarin,” Journal of Biomaterials Applications, vol. 28, no. 6, pp. 887–896, 2014. View at: Publisher Site | Google Scholar
  25. M. Sun, S. Nie, X. Pan, R. Zhang, Z. Fan, and S. Wang, “Quercetin-nanostructured lipid carriers: characteristics and anti-breast cancer activities in vitro,” Colloids and Surfaces B: Biointerfaces, vol. 113, pp. 15–24, 2014. View at: Publisher Site | Google Scholar
  26. E. Esposito, L. Ravani, M. Drechsler et al., “Cannabinoid antagonist in nanostructured lipid carriers (NLCs): design, characterization and in vivo study,” Materials Science and Engineering C, vol. 48, pp. 328–336, 2015. View at: Publisher Site | Google Scholar
  27. G. Fang, B. Tang, Y. Chao et al., “Cysteine-functionalized nanostructured lipid carriers for oral delivery of docetaxel: a permeability and pharmacokinetic study,” Molecular Pharmaceutics, vol. 12, no. 7, pp. 2384–2395, 2015. View at: Publisher Site | Google Scholar
  28. R. Qi, Y.-Z. Li, C. Chen et al., “G5-PEG PAMAM dendrimer incorporating nanostructured lipid carriers enhance oral bioavailability and plasma lipid-lowering effect of probucol,” Journal of Controlled Release, vol. 210, pp. 160–168, 2015. View at: Publisher Site | Google Scholar
  29. T.-H. Wu, F.-L. Yen, L.-T. Lin, T.-R. Tsai, C.-C. Lin, and T.-M. Cham, “Preparation, physicochemical characterization, and antioxidant effects of quercetin nanoparticles,” International Journal of Pharmaceutics, vol. 346, no. 1-2, pp. 160–168, 2008. View at: Publisher Site | Google Scholar
  30. H. Li, X. Zhao, Y. Ma, G. Zhai, L. Li, and H. Lou, “Enhancement of gastrointestinal absorption of quercetin by solid lipid nanoparticles,” Journal of Controlled Release, vol. 133, no. 3, pp. 238–244, 2009. View at: Publisher Site | Google Scholar
  31. J. Das Neves and B. Sarmento, “Precise engineering of dapivirine-loaded nanoparticles for the development of anti-HIV vaginal microbicides,” Acta Biomaterialia, vol. 18, pp. 77–87, 2015. View at: Publisher Site | Google Scholar
  32. H. Rostami and S. M. T. Gharibzahedi, “Microwave-assisted extraction of jujube polysaccharide: optimization, purification and functional characterization,” Carbohydrate Polymers, vol. 143, pp. 100–107, 2016. View at: Publisher Site | Google Scholar
  33. Z. Ye, W. Wang, Q. Yuan et al., “Box-Behnken design for extraction optimization, characterization and in vitro antioxidant activity of Cicer arietinum L. hull polysaccharides,” Carbohydrate Polymers, vol. 147, pp. 354–364, 2016. View at: Publisher Site | Google Scholar
  34. M. Pradhan, D. Singh, S. N. Murthy, and M. R. Singh, “Design, characterization and skin permeating potential of Fluocinolone acetonide loaded nanostructured lipid carriers for topical treatment of psoriasis,” Steroids, vol. 101, article no. 7791, pp. 56–63, 2015. View at: Publisher Site | Google Scholar
  35. S. K. Hobbs, W. L. Monsky, F. Yuan et al., “Regulation of transport pathways in tumor vessels: role of tumor type and microenvironment,” Proceedings of the National Academy of Sciences of the United States of America, vol. 95, no. 8, pp. 4607–4612, 1998. View at: Publisher Site | Google Scholar
  36. P. Dadhania, P. R. Vuddanda, A. Jain, S. Velaga, and S. Singh, “Intranasal delivery of asenapine loaded nanostructured lipid carriers: formulation, characterization, pharmacokinetic and behavioural assessment,” RSC Advances, vol. 6, no. 3, pp. 2032–2045, 2016. View at: Publisher Site | Google Scholar
  37. J. Li, J. Wu, J. Zhang, Y. Wang, L. Fang, and Q. Shen, “Oral bioavailability and evaluation of docetaxel-nicotinamide complex loaded chitosan nanoparticles,” RSC Advances, vol. 6, no. 42, pp. 35354–35364, 2016. View at: Publisher Site | Google Scholar
  38. J.-H. Park, S.-J. Ban, T. Ahmed et al., “Development of DH-I-180-3 loaded lipid nanoparticle for photodynamic therapy,” International Journal of Pharmaceutics, vol. 491, no. 1-2, pp. 393–401, 2015. View at: Publisher Site | Google Scholar
  39. H. Chen, Y. Wang, Y. Zhai, G. Zhai, Z. Wang, and J. Liu, “Development of a ropivacaine-loaded nanostructured lipid carrier formulation for transdermal delivery,” Colloids and Surfaces A: Physicochemical and Engineering Aspects, vol. 465, pp. 130–136, 2015. View at: Publisher Site | Google Scholar
  40. B. Gupta, B. K. Poudel, T. H. Tran et al., “Modulation of pharmacokinetic and cytotoxicity profile of imatinib base by employing optimized nanostructured lipid carriers,” Pharmaceutical Research, vol. 32, no. 9, article no. 1673, pp. 2912–2927, 2015. View at: Publisher Site | Google Scholar
  41. C. Liu and C. Wu, “Optimization of nanostructured lipid carriers for lutein delivery,” Colloids and Surfaces A: Physicochemical and Engineering Aspects, vol. 353, no. 2-3, pp. 149–156, 2010. View at: Publisher Site | Google Scholar
  42. S. Bose and B. Michniak-Kohn, “Preparation and characterization of lipid based nanosystems for topical delivery of quercetin,” European Journal of Pharmaceutical Sciences, vol. 48, no. 3, pp. 442–452, 2013. View at: Publisher Site | Google Scholar
  43. F. Tamjidi, M. Shahedi, J. Varshosaz, and A. Nasirpour, “Design and characterization of astaxanthin-loaded nanostructured lipid carriers,” Innovative Food Science and Emerging Technologies, vol. 26, pp. 366–374, 2014. View at: Publisher Site | Google Scholar
  44. H. Bunjes and T. Unruh, “Characterization of lipid nanoparticles by differential scanning calorimetry, X-ray and neutron scattering,” Advanced Drug Delivery Reviews, vol. 59, no. 6, pp. 379–402, 2007. View at: Publisher Site | Google Scholar
  45. T. H. I. Tran, T. Ramasamy, D. H. I. Truong, H.-G. Choi, C. S. O. Yong, and J. O. H. Kim, “Preparation and characterization of fenofibrate-loaded nanostructured lipid carriers for oral bioavailability enhancement,” AAPS PharmSciTech, vol. 15, no. 6, pp. 1509–1515, 2014. View at: Publisher Site | Google Scholar

Copyright © 2017 Wei Huang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


More related articles

2191 Views | 690 Downloads | 4 Citations
 PDF  Download Citation  Citation
 Download other formatsMore
 Order printed copiesOrder

Related articles

We are committed to sharing findings related to COVID-19 as quickly and safely as possible. Any author submitting a COVID-19 paper should notify us at help@hindawi.com to ensure their research is fast-tracked and made available on a preprint server as soon as possible. We will be providing unlimited waivers of publication charges for accepted articles related to COVID-19. Sign up here as a reviewer to help fast-track new submissions.